<DOC>
	<DOCNO>NCT02923804</DOCNO>
	<brief_summary>This study prospective , randomize , placebo-controlled , double-blind trial determine effect high concentrate omega-3 capsule omega-3 status patient non-alcoholic fatty liver .</brief_summary>
	<brief_title>Evaluation MF4637 Correcting Omega-3 Nutritional Deficiency NAFLD Patients</brief_title>
	<detailed_description>Subjects non-alcoholic fatty liver ( simple steatosis ) confirm within last year ultrasound image modality recruit study . Subjects randomize treatment arm high concentrate capsule placebo 6 month treatment period.Omega-3 content red blood cell ( omega-3 index ) measure primary endpoint assessment . Quantitative MRI perform determine effect liver fat content .</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Malnutrition</mesh_term>
	<criteria>1 . Documented history clinical diagnosis NAFLD ultrasound , MRI biopsy within one ( 1 ) year prior screening ( V1 ) . If diagnostic test date great one ( 1 ) year , abdominal ultrasound repeat ( V1 ) must confirm diagnosis NAFLD . 2 . Men woman , ≥18 year age . 3 . BMI 18.0 39.9 kg/m2 . 4 . Nonsmokers ( &gt; 3 month nonsmoking ) . 5 . If statin regimen , history ( &gt; 1 month stable dose ) take statin medication ( HMGCoA reductase inhibitor example : Lipitor , Zocor , Crestor , Pravachol , Lescol , Livalo , etc ) . 6 . Able understand cooperate study procedure , sign write informed consent prior study procedure . 1 . Diagnosis NASH . 2 . Bilirubin &gt; 2x ULN . 3 . Other cause liver inflammation include Hepatitis A , B C , HIV , confirm suspected cirrhosis , Wilson 's disease , autoimmune hepatitis , hemochromatosis , alcoholic steatohepatitis , pancreatitis , prescription medication know cause liver damage , know hepatotoxic . 4 . Subjects history bariatric surgery . 5 . Significant weight loss ( &gt; 5 % body weight ) rapid weight loss ( &gt; 1.6 kg/week ) , within six month screen . 6 . Current recent ( within six month screen ) history significant gastrointestinal , renal , pulmonary , hepatic biliary disease , endocrine disease invasive weight loss treatment ( Type II Diabetes permit , stable ( &gt; 3 month ) thyroid disorder ) . 7 . Individual take prescription overthecounter medication ( include dietary supplement , see Appendix 1 ) know alter lipid metabolism , within four ( 4 ) week randomization . These medication include ( limited ) follow : bile acid sequestrants , cholesterol absorption inhibitor , niacin fibrates , 8 . Individuals take prescription omega3 fatty acid . 9 . Use supplement include Omega3s Omega6s , oilbased supplement , phytosterols , Vitamin E , prebiotics probiotic , weight loss supplement within four ( 4 ) week randomization ( multivitamins mineral contain Vitamin E permit ) . 10 . Use systemic corticosteroid , androgen ( except androgen hypogonadism restore normal level ) , phenytoin , erythromycin macrolides , thiazolidinediones ( e.g . pioglitazone ) , thyroid hormone ( except stabledose thyroid replacement therapy four ( 4 ) week prior enrollment ) . 11 . Use anticoagulant warfarin ( Coumadin ) , dabigatran ( Pradaxa ) , apixaban ( Eliquis ) rivaroxaban ( Xarelto ) . NOTE : Antiplatelet agent Plavix allow . 12 . Pregnant lactate woman woman childbearing potential , use approve method contraception . A woman consider childbearing potential unless posthysterectomy , one year postmenopausal , one year posttubal ligation . 13 . History significant cardiovascular coronary heart disease ( CVD CHD ) define coronary artery bypass procedure , coronary stent angioplasty , myocardial infarction previous six ( 6 ) month . 14 . History cancer , nonmelanoma skin cancer basal cell carcinoma , within previous five year . 15 . Poorly control uncontrolled hypertension ( systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥95 mmHg ) . 16 . Recent history prolong alcohol ( &gt; 3 month ) use ( within past 6 month ) excessive alcohol use , define &gt; 14 drink per week ( one drink = 12 oz . beer , 4 oz . wine , 1.5 oz . hard liquor ) . 17 . Exposure investigational agent within four ( 4 ) week prior Visit 1 . 18 . Subjects plan undergo surgery study period 1 month study 19 . Any serious psychiatric disease disorder , , opinion investigator , would preclude subject participate study . 20 . Any known intolerance investigational ingredient medical food . 21 . Has condition Investigator believe would interfere evaluation subject , may put subject undue risk course study , include potentially abnormal lab result , due traumatic event .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>steatosis</keyword>
	<keyword>NAFL</keyword>
	<keyword>NAFLD</keyword>
	<keyword>Polyunsaturated fatty acid</keyword>
	<keyword>omega-3</keyword>
	<keyword>EPA</keyword>
	<keyword>DHA</keyword>
	<keyword>fish oil</keyword>
</DOC>